Health Care
Biotech and Pharmaceuticals
featured
Drugmaker Merck & Co Inc will restructure its U.S. sales team, cutting 1,800 sales positions and adding 960 in c chronic care. » Read More
By: Jessica Mathews, special to CNBC.com
Research into fasting as a regular part of diet could help in the fight against food-related diseases, including heart disease and diabetes. » Read More |
By: Douglas Quenqua, special to CNBC.com
Pharmaceutical company Sanofi has engineered a three-pronged antibody that attacks the AIDS virus and is a roadblock for HIV infection. » Read More |
CNBC's Meg Tirrell shares details of the FDA'a approval of Gilead's new immunotherapy drug to treat patients with non-Hodgkin lymphoma. » Read More |
More
Roche's third-quarter sales rose 6 percent to 13.1 billion Swiss francs ($13.37 billion).
Jim Cramer explains why the bulls are right and the stock of Johnson & Johnson is worth owning.
Jim Cramer caught up with JJ Bienaime, the chairman and CEO of BioMarin, who spoke to his company's promising pipeline of drugs.
Jim Cramer explains why the bulls are right and the stock of Johnson & Johnson is worth owning.
The drug falls under a class of newer products which aim to help the immune system identify and target cancerous cells.
CNBC's Meg Tirrell reports on the latest patent lawsuits from the Saint Regis Mohawk Tribe.
The tribe is a co-plaintiff with SRC Labs, which claims its data processing technology patents have been infringed for years.
The makers of cancer drugs also make vials with too much medication for many patients, ProPublica reports.
Citi increased its peak Keytruda sales forecast on the drug to $16 billion from $9 billion.
Health insurer Anthem says it will start managing its billions of dollars of patient prescriptions itself in 2020.
Regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer.
"Prescription drug prices are out of control. The drug prices have gone through the roof," Trump says at a Cabinet meeting.
Shifts in the patent system over the past decade have weakened companies' abilities to protect innovations, the Financial Times reports.
Credit Suisse shared with clients its favorite biotechnology stock picks ahead of the third-quarter earnings season.
CNBC's Meg Tirrell reports on Spark Therapeutics shares jumping after the FDA panel votes in favor of the company's gene therapy.
But the company said the impact was mitigated by positive performance in other areas of the business.
Contact Biotech and Pharma
-
CNBC NEWSLETTERS
Get the best of CNBC in your inbox
Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.▲Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.
Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.
